On 27 June 2024 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation No. 63/2024 of the drug Acarizax (standardized allergen extract of house dust mite, D. pteronyssinus, D. farina) for the indication: Treatment of adult patients (18 to 65 years of age) diagnosed on the basis of clinical history and a positive house dust mite allergy test (spot skin tests and/or specific immunoglobulin E) and at least one of the following conditions:
- moderate to severe allergic rhinitis caused by house dust, persisting despite medication to relieve symptoms;
- bronchial asthma caused by house dust allergy, not controlled well with inhaled corticosteroids accompanied by moderate to severe allergic rhinitis caused by house dust
Publication in Public Information Bulletin (BIP) >>